Abstract Details

Title 24 Cases Anti-NMDAR Encephalitis in China

Topic Infections/AIDS/Prion Disease

Presentation(s) S16 - (-)

Poster/Presentation
Number 002

Objective

Background Anti-NMDA-receptor (NMDAR) encephalitis is a severe disorder that occurs in association with antibodies to the NR1 subunit of the NMDAR and results in a characteristic syndrome. Prompt diagnosis and treatment are important to obtain full recovery.

Design/Methods More than one hundred serum and CSF samples of patients were examined for NMDAR antibodies. 24 of them had NMDAR antibodies. All patients were treated with first-line treatment (tumor removal and corticosteroids, IVIg or plasma exchange) or second-line immunotherapy (rituximab, cyclophosphamide, or both).

Results More than one hundred serum and CSF samples of patients were examined for NMDAR antibodies. Of these, 24(median13.2 years, range 2-32 years)were tested positive for anti-NMDAR antibodies. And they were consisted of 12 (50%) women and 12 (50%) men. Only one patient has prodromal symptoms that resemble a viral process. The common presenting symptoms were psychosis, memory deficits, seizures, abnormal movements, and autonomic and breathing instability. 13 (54%) patients were younger than 12 years, and the first symptom were seizures (46%), speech and movement disorder (23%) , and disturbance of consciousness (15%). 9 (38%) patients were older than 17 years, but the first symptom were often psychiatric (56%). Ovarian teratomas were detected in 3 patients older than 15 years. The cerebrospinal fluid(CSF)was abnormal in 55% of patients. Findings include moderate lymphocytic pleocytosis and mildly increased protein concentration. 57% of patients had T2 or FLAIR signal hyperintensity in hippocampi, cerebral cortex, thalamus, basal ganglia and brainstem. 95% of patients had abnormal EEG.

Conclusions Anti-NMDAR encephalitis is highly predictable, recognizable on clinical grounds and can be confirmed with the demonstration of NMDAR antibodies. And early diagnosis and treatment should be emphasized.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��